Cloned airway basal progenitor cells to repair fibrotic lung through re-epithelialization

Yu Zhao, Yueqing Zhou, Weipan Zhang, Mingzhe Liu, Jun Duan, Xiaopeng Zhang, Qiwang Ma, Yujia Wang, Yuzhen Zhang, Zhongliang Guo (), Ting Zhang () and Wei Zuo ()
Additional contact information
Yu Zhao: Tongji University
Yueqing Zhou: Regend Therapeutics
Weipan Zhang: Tongji University
Mingzhe Liu: Tongji University
Jun Duan: Tongji University
Xiaopeng Zhang: Tongji University
Qiwang Ma: BGI-Shenzhen
Yujia Wang: Regend Therapeutics
Yuzhen Zhang: Tongji University
Zhongliang Guo: Tongji University
Ting Zhang: Regend Therapeutics
Wei Zuo: Tongji University

Nature Communications, 2025, vol. 16, issue 1, 1-16

Abstract: Abstract Irreversible damage of the lung epithelium in idiopathic pulmonary fibrosis (IPF) patients causes high mortality worldwide, with no lung repair approaches available currently. Here we show that in murine and monkey models, the KRT5+ P63+ progenitor cells in airway basal layer can enter the alveolar area post fibrotic injury. Aided with an automated culture system, we clone and characterize airway basal progenitor cells from 44 donors with various lung conditions. Transplantation of human progenitor cells into the mouse lung efficiently re-epithelializes the injured alveolar area, forms new respiratory tract and saccule-like structures, which ameliorates fibrotic lesions and improves survival of mice. Mechanistically, the engrafted human progenitor cells do not function by differentiating into mature alveolar cells in mouse lung; instead, they differentiate into saccular cells expressing multiple tight junction proteins such as CLDN4, which help the lung to re-establish epithelial barriers. Furthermore, by cloning P63+ airway basal progenitors from larger mammals and birds, we construct multiple lung-chimerism animals and uncover the evolutionarily conserved roles of these progenitor cells in lung repair. Overall, our data highlight the fate of airway basal progenitor cells in fibrotic lung and provide a potential therapeutic strategy for pulmonary diseases that lack inherent recovery mechanisms.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-56501-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56501-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-56501-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().